BidaskClub cut shares of Atrion (NASDAQ:ATRI) from a buy rating to a hold rating in a report released on Thursday morning.
Separately, ValuEngine raised Atrion from a hold rating to a buy rating in a research note on Monday, February 4th.
Shares of ATRI stock opened at $814.57 on Thursday. The company has a market cap of $1.48 billion, a PE ratio of 43.30 and a beta of 0.43. Atrion has a 1-year low of $560.65 and a 1-year high of $815.00.
Hedge funds have recently made changes to their positions in the company. PNC Financial Services Group Inc. acquired a new position in shares of Atrion during the 4th quarter worth approximately $130,000. Amundi Pioneer Asset Management Inc. acquired a new position in shares of Atrion during the 4th quarter worth approximately $148,000. Quantamental Technologies LLC acquired a new position in shares of Atrion during the 4th quarter worth approximately $149,000. Legal & General Group Plc raised its stake in shares of Atrion by 7.8% during the 4th quarter. Legal & General Group Plc now owns 249 shares of the medical instruments supplier’s stock worth $185,000 after buying an additional 18 shares during the period. Finally, Jane Street Group LLC acquired a new position in shares of Atrion during the 4th quarter worth approximately $202,000. 61.74% of the stock is owned by institutional investors and hedge funds.
Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
Featured Story: Options Trading – What is a Straddle?
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.